Lumobiotics develops light-controllable peptide drugs as safe cytolytic agents for treatment of solid cancers and localized infectious diseases. We are dedicated to fostering the development of chemotherapeutic based on the technology platform, utilizing molecular photoswitches. As a university Spin-off we perform rigorous science translating into societal benefit.
Management team
Co-founder
CEO
Co-founder
Co-founder
COO
Scientific advisors
Co-founder
Scientific advisor
Co-founder
Scientific advisor
External advisors
Immuno-oncology discovery program is being implemented under scientific advise of Prof Viktor Umansky (German Cancer Research Center (DKFZ), Heidelberg, Germany)
